DrugDashboards

Metoclopramide

metoclopramide · METOCLOPRAMIDE HYDROCHLORIDE 5 mg/mL · Injection, Solution · Intramuscular; Intravenous · Hospira, Inc.

NDC 00409-3414-11 · 25 VIAL, SINGLE-DOSE in 1 TRAY / 2 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. The price has held steady around $0.5290 per mL over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 2× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.5290per MLinvoice-surveyed acquisition cost · Jul 22, 2026
  • Medicare Part B pays (ASP+6%)$1.00per billing unit (10 MG)HCPCS J2765 · Jul 1, 2026
  • Federal contracts pay (FSS)$23.87per package of 25X2MLPfizer Inc. · Feb 15, 2025

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.25$0.5$0.75Oct 2024Sep 2026$0.529
16 price points · per ML · held since Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$31.06
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 10 MG
$1.004
HCPCS J2765 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$101,425
28,323 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

10Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for metoclopramide (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 2× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA073118
TE code
AP
Approval date
Jan 17, 1991
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedSep 24, 2013
    Hospira Inc.Presence of Particulate Matter: Potential vendor glass issue - glass spiticules (glass strands) were identified during site inspection of the vials.

Manufacturers of metoclopramide (Injection, Solution)

LabelerStrengthFirst seenLast seen
Cardinal Health 107, LLCMETOCLOPRAMIDE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
HF Acquisition Co LLC, DBA HealthFirstMETOCLOPRAMIDE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.METOCLOPRAMIDE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
Teva Parenteral Medicines, Inc.METOCLOPRAMIDE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 3, 2026
HF Acquisition Co LLC, DBA HealthFirstMETOCLOPRAMIDE HYDROCHLORIDE 10 mg/2mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLCMETOCLOPRAMIDE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLC.METOCLOPRAMIDE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026
ProPharma DistributionMETOCLOPRAMIDE HYDROCHLORIDE 5 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Metoclopramide — NDC 00409-3414-11," retrieved September 3, 2026, https://drugdashboards.com/drug/00409341411.

Free to cite with attribution — see how the data is put together.